p-ethylphenyl p-tolyl sulfone | 5184-66-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: p-ethylphenyl p-tolyl sulfone
• 英文别名: 1-ethyl-4-tosylbenzene；(4-ethyl-phenyl)-p-tolyl sulfone；(4-Aethyl-phenyl)-p-tolyl-sulfon；4-Methyl-4'-ethyl-diphenylsulfon；1-Ethyl-4-[(4-methylphenyl)sulfonyl]benzene；1-(4-ethylphenyl)sulfonyl-4-methylbenzene
• CAS: 5184-66-7
• 化学式: C₁₅H₁₆O₂S
• 分子量: 260.357
• InChiKey: DZAPWJKAIIHAJY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  42.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  p-ethylphenyl p-tolyl sulfone 在 chromium(VI) oxide 、 溶剂黄146 作用下， 生成 4,4'-二羧基联苯砜
  参考文献：
  名称：

  Buehler; Masters, Journal of Organic Chemistry, 1939, vol. 4, p. 292,293

  摘要：

  DOI：
• 作为产物：
  描述：

  乙基苯 、 对甲苯磺酰氯 在 三氯化铝 作用下， 生成 p-ethylphenyl p-tolyl sulfone
  参考文献：
  名称：

  THE IDENTIFICATION OF AROMATIC SULFONES

  摘要：

  DOI：

  10.1021/jo01215a007

文献信息

• Sulfonylation of Bismuth Reagents with Sulfinates or SO₂ through Bi^III/Bi^V Intermediates
  作者：Fengqian Zhao、Xiao-Feng Wu

  DOI：10.1021/acs.organomet.1c00339

  日期：2021.8.9

  Under oxidative conditions, triarylbismuthines and sulfinates were transformed into diaryl sulfones. A transition-metal-like two-electron redox process at the Bi center was achieved in this reaction. Sulfur dioxide generated in situ can also replace sulfinates to deliver the corresponding symmetric diaryl sulfones. A rational mechanism for this reaction was also proposed that involves a Bi(III)–Bi(V)

  探索主族元素催化活性的研究很有吸引力。我们在此报告我们对铋试剂与亚磺酸盐或 SO 2替代物磺酰化的研究。在氧化条件下，三芳基铋和亚磺酸盐转化为二芳基砜。该反应在Bi中心实现了类似过渡金属的双电子氧化还原过程。原位生成的二氧化硫也可以替代亚磺酸盐以提供相应的对称二芳基砜。还提出了该反应的合理机制，涉及 Bi(III)-Bi(V) 流形。
• MANUFACTURE, METHOD AND USE OF ACTIVE SUBSTANCE-RELEASING MEDICAL PRODUCTS FOR PERMANENTLY KEEPING BLOOD VESSELS OPEN
  申请人：Hoffmann Erika

  公开号：US20100063585A1

  公开（公告）日：2010-03-11

  The invention relates to stents and catheter balloons having optimized coatings for eluting rapamycin as well as methods for manufacturing these coatings.

  本发明涉及具有优化涂层以释放雷帕霉素的支架和导管球囊，以及制造这些涂层的方法。
• IMIDAZO[1,2-beta]PYRIDAZINE AND PYRAZOLO[1,5-alpha]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS
  申请人：Bearss David J.

  公开号：US20080261988A1

  公开（公告）日：2008-10-23

  The present invention provides protein kinase inhibitors comprising imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine compounds of the following structure (I) and (II): or a stereoisomer, prodrug or pharmaceutically acceptable salt thereof, wherein R, R 1 , R 2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer and other Pim kinase-associated conditions are also disclosed.

  本发明提供了蛋白激酶抑制剂，包括以下结构（I）和（II）的咪唑[1,2-b]吡啶和吡唑[1,5-a]嘧啶化合物或其立体异构体、前药或药物可接受的盐，其中R、R1、R2和X如本文所定义。还公开了使用这些抑制剂治疗癌症和其他Pim激酶相关疾病的组合物和方法。
• IMIDAZO[1,2-B]PYRIDAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS
  申请人：Bearss David J.

  公开号：US20110281863A1

  公开（公告）日：2011-11-17

  The present invention provides protein kinase inhibitors comprising imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine compounds of the following structure (I) and (II): or a stereoisomer, prodrug or pharmaceutically acceptable salt thereof, wherein R, R 1 , R 2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer and other Pim kinase-associated conditions are also disclosed.

  本发明提供蛋白激酶抑制剂，包括以下结构（I）和（II）的咪唑并[1,2-b]吡啶和吡唑并[1,5-a]嘧啶化合物的立体异构体、前药或药物可接受的盐，其中R、R1、R2和X如本文所定义。还公开了在治疗癌症和其他Pim激酶相关疾病中使用这些化合物的组合物和方法。
• HETEROCYCLIC PROTEIN KINASE INHIBITORS
  申请人：Xu Yong

  公开号：US20140329807A1

  公开（公告）日：2014-11-06

  The present invention provides protein kinase having one of the following structures (I), (II) or (III): or a stereoisomer, prodrug, tautomer or pharmaceutically acceptable salt thereof, wherein R, R 1 , R 2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer, autoimmune, inflammatory and other Pim kinase-associated conditions are also disclosed.

  本发明提供具有以下结构之一（I），（II）或（III）的蛋白激酶：或其立体异构体，前药，互变异构体或药学上可接受的盐，其中R，R1，R2和X如本文所定义。还公开了在治疗癌症，自身免疫，炎症和其他Pim激酶相关疾病中使用相同的组合物和方法。